小鼠非清髓性单倍体相合骨髓移植模型的建立

目的建立小鼠非清髓性单倍体相合骨髓移植模型,为研究移植前诱导免疫耐受或移植后输注供者细胞促进植入提供研究平台。方法以CB6F1雌性小鼠为受鼠,移植前1 d予450 cGy全身照射（TBI）后,随机分为2组,实验组移植0 d输注C57BL/6雄性小鼠骨髓有核细胞5×107/只,对照组不予移植。然后监测受鼠造血恢复、检测供鼠性别决定基因（SRY）判断植入情况,以及外周血供者细胞尤其CD3＋细胞嵌合状态,同时观察小鼠急性移植物抗宿主病（aGVHD）的发生情况。结果对照组小鼠均存活,仅表现轻度aGVHD,血象移植后30 d内基本恢复正常水平。实验组小鼠SRY基因在移植后＋14 d、＋30 d、＋60 d时检测PCR结果均阳性,供鼠外周血淋巴细胞、单核细胞、粒细胞嵌合率在移植后14 d分别为23.8%、36.9%%、19.4%;30 d分别为49.9%、53.2%、54.4%;60 d分别为67.6%、51.6%、56.9%,其中CD3＋细胞嵌合率分别为4.4%、21.2%、54.4%。结论 450 cGyTBI的非清髓性预处理方案,可以诱导受鼠免疫耐受、供者骨髓细胞植入,嵌合率处于中低水平混合嵌合状态。     

Adenovirus-mediated<Emphasis Type="Italic">CTLA4-FasL</Emphasis> gene transfer prevents autoimmune diabetes in mice induced by multiple low doses of streptozotocin

Type 1 diabetes is the result of a selective destruction of insulin-producing β cells in pancreatic islets by autoreactive T cells. Depletion of autoreactive T cell through apoptosis may be a potential strategy for the prevention of autoimmune diabetes. Simultaneous stimulation of Fas-mediated pathway and blockade of costimulation by a CTLA4-FasL fusion protein has been reported to lead to substantial inhibition of mixed lymphocyte reaction and enhanced in vitro apoptosis of peripheral lymphocytes. To test the feasibility of CTLA4-FasL-based gene therapy to prevent autoimmune diabetes, we developed recombinant adenovirus containing human CTLA4-FasL gene (AdCTLA4-FasL). A single injection of 2×10~8 plaque forming units (PFU) of AdCTLA4-FasL via tail vein dramatically reduced the incidence of autoimmune diabetes in mice induced by multiple low doses of streptozotocin. AdCTLA4-FasL administration maintained islet insulin content, significantly increased apoptosis of pancreatic lymphocytes, quantitatively     

Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance

Allogeneic reactions are the major limitation to organ transplantation. These are manifested as rejection of the grafted tissue, and also, in the case of bone marrow transplantation (BMT), graft-versus-host disease (GVHD). Recent methods of avoiding GVHD, by depleting T cells from donor marrow, have led to an increased incidence of marrow graft rejection. Current recipient conditioning protocols involving drugs or irradiation cannot safely be increased, so alternatives must be found. Monoclonal antibodies can be used to control immune responses in vivo, and would be useful in this context if we could define and deplete the cells responsible for marrow rejection. We show here that elimination of residual L3T4+ and Lyt-2+ cells from mice receiving fully mismatched bone marrow abrogates rejection and promotes tolerance to donor-type skin grafts, even in sub-lethally irradiated recipients.     

Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts

Clinical organ transplantation between genetically disparate individuals currently requires the use of chemotherapeutic agents to suppress the rejection reaction. The deleterious side effects of these reagents and their inability to prevent rejection completely has led to a continuing search for methods to induce specific transplantation tolerance in adult recipients. Numerous experimental animal models utilizing irradiation and bone marrow transplantation coincident with organ transplantation have been proposed. Bone marrow transplantation, however, has its own major complications, including graft-versus-host reactions and immunoincompetence, probably resulting from a failure of appropriate immune cell interactions in the reconstituted host. We have now attempted to overcome these difficulties by reconstituting the irradiated host with T-cell depleted bone marrow containing both host (syngeneic) and donor (allogeneic or xenogeneic) components. This technique leads to long-term survival of the reconstituted animals and specific prolongation of subsequent skin grafts of donor type. Animals reconstituted in this fashion are fully reactive to third-party allografts and xenografts and do not appear to manifest signs of graft-versus-host disease.     

无关供者骨髓移植治疗多次复发性急性白血病

文章探讨无关供者骨髓移植治疗多次复发急性白血病的疗效 .经改良 Bucy方案预处理后对一例第三次复发的急粒患者行无关供者骨髓移植 ,同时给防治 GVHD、抗感染治疗 .结果 + 2 1天骨髓在患者体内植活 ,+ 35天细胞染色体分析呈供者型 ( 4 6,XX.正常核型 ) ,+ 84天血型转换成供者型 ,至今已无病生存超过 6个月 .结果表明 ,无关供者骨髓移植对多次复发的急性白血病患者具有治疗价值     

导入蓖麻毒蛋白的供体淋巴细胞在小鼠皮肤移植中产生的特异免疫耐受

以小鼠为研究对象进行皮肤移植,受体为BALB/C鼠,供体为C₅₇BL/6鼠。用氯化钙介导蓖麻毒蛋白(ricin)进入供体鼠的脾细胞制成毒细胞,适时地注入受体体内。带有蓖麻毒蛋白供体脾细胞,一方面可提供特异移植抗原(主要组织相容性抗原)使特异的T,B淋巴细胞识;另一方面,它被识别裂解后,释放蓖麻毒蛋白,又可杀伤与其识别的T,B淋巴细胞,使受体对供体移植物产生耐受。实验共设两组,在皮肤移植前后分别用包埋蓖麻毒蛋白的供体脾细胞处理,两组移植皮片存活时间均比相应对照组有显著延长(t＞t_0.01)。混合淋巴细胞培养实验和淋巴细胞转化实验证明了实验组对供体细胞的免疫应答及免疫细胞的分化能力均受到抑制。对这一新设想进行了初步的研究。     

大鼠口服免疫耐受与皮肤移植的研究

目的利用口服供者脾细胞延长受者大鼠皮肤存活时间,检测调节性T细胞在移植前后的变化,探讨口服免疫耐受的机制。方法以纯系SD大鼠为供者,纯系Wistar大鼠为受者,行异体皮肤移植,将24只受者大鼠随机分为A组（对照组,口服PBS）、B组（每日口服SD大鼠脾细胞1×10^7个）,C组（每日口服SD大鼠脾细胞5×10^7个）,对受体进行450Rad^60Co照射,然后检测受者外周血及脾脏CD4＋CD25＋、CD8＋CD28-调节性T细胞（Treg）,并对受者进行供者脾细胞导管灌胃,每次口服5×10^7个细胞,每日一次,7d后检查迟发型超敏反应（DTH）,并行皮肤移植,观察移植皮肤的存活时间,复查Treg两次。结果口服脾细胞后,DTH反应均出现明显的抗原特异性降低;C组的皮肤移植存活时间达到19．17d±1．94d,与前两组比较差异有显著性（P〈0．01）。在口服供体脾细胞延长皮肤移植存活大鼠（C组）的外周血及脾脏中CD8＋CD28-Treg均比口服前明显增高（P〈0．01）,并能维持2周以上。结论口服抗原可以引起受者对异基因抗原的特异性免疫反应降低,使受者的皮肤移植存活期延长,CD8＋CD28-Treg在口服免疫耐受的机制中发挥了重要作用。     

Clonal nature of mast-cell clusters formed in W/Wv mice after bone marrow transplantation.

We have recently found that the number of mast cells in the skin of adult W/Wv mice is less than 1% of that observed in congeneic +/+ mice, and that no mast cells are detected in other tissues of W/Wv mice. After the transplantation of bone marrow cells from congeneic +/+ mice, the number of mast cells in the skin, stomach, caecum and mesentery of the W/Wv mice increased to levels similar to those of the +/+ mice. Study of the mast-cell number in the W/Wv mice at various times after transplantation suggested to use that mast cells might develop in groups, particularly in the skin and mesentery. In this report, we have attempted to elucidate the possible clonal origin of such mast-cell clusters from a single precursor cell, using giant granules of beige (C57BL/6-bgJ/bgJ, Chediak-Higashi syndrome) mice as a marker to identify the origin of the mast cells (Fig. 1). We found that when WB-W/+xC57BL/6-Wv (WBB6F1)-W/Wv mice were injected with a mixture of bone marrow cells from beige C57BL/6 mice and normal C57BL/6 mice, more than 95% of mast-cell clusters consisted of either beige-type cells alone or normal-type cells alone. We conclude, therefore, that the cluster of mast cells originated from a single precursor cell.     

Advances in tissue engineering

Tissue engineering is a newly developed specialty involved in the construction of tissues and organs either in vitro or in vivo. Tremendous progress has been achieved over the past decade in tisse construction as well as in other related areas, such as bone marrow stromal cells, embryonic stem cells and tissue progenitor cells. In our laboratory, tissues of full-thickness skin, bone, cartilage and tendon have been successfully engineered, and the engineered tissues have repaired full-thickness skin wound, cranial bone defects, articular cartilage defects and tendon defects in animals. In basic research areas, bone marrow stromal cells have been induced and transformed into osteoblasts and chondrocytes in vitro. Mouse embryo stem cell lines we established have differentiated into neuron precursor, cardiac muscle cells and epithelial cells. Genetic modifications of seed cells for promoting cell proliferation, delaying cell aging and inducing immune tolerance have also been investigated.     

小鼠同种异基因皮肤移植模型的建立

目的：为移植免疫及药物免疫机理研究建立小鼠同种异基因皮肤移植动物模型。方法：受体BALB/c分为A～E共5组,即对照组,5．0、7．5、10、20mg／kg环孢菌素A(CsA)剂量组,通过背-背法进行C57BL／6的全厚皮皮片移植,以探求通过较小剂量CsA及优化实验条件和护理方式建立供免疫机理研究的动物试验平台。结果：5．0、7．5、10mg/kg组相对于对照组皮片排斥时间无明显差别,而20mg/kg组植皮能较长时间存活。结论：20mg／kg的CsA剂量可以经济,快速地建立小鼠同种异基因移植动物模型。     

Epidermal Langerhans cells are derived from cells originating in bone marrow

Langerhans cells constitute a morphologically well characterised subpopulation (3--8%) of mammalian epidermal cells which, in contrast to the bulk of epidermal cells, bear Fc-IgG and C3 receptors, express immune response-associated (Ia) antigens and function as antigen-presenting cells and allogeneic stimulatory cells to primed T lymphocytes. The ontogeny of Langerhans cells has been a subject of considerable debate since their discovery. Although some studies suggest that Langerhans cells are of mesenchymal as opposed to neural or melanocytic origin, direct evidence for this has not been presented. In this study we demonstrate that, after 3 weeks, most of the Langerhans cells (LC) in parenteral skin which had been transplanted on to F1 hybrids were of recipient origin whereas keratinocytes remained of donor origin; this indicates that the LC are derived from a mobile pool of cells. Furthermore, in studies of skin from radiation-induced bone marrow chimaeric animals we found that, depending on the strain combination, up to 80% of the epidermal LC were derived from the bone marrow of the donor animals.     

Lymphotactin enhances the in-vitro immune efficacy of dendritoma formed by dendritic cells and mouse hepatocellular carcinoma cells

Objective: To investigate the in-vitro antitumor immune responses of dendritoma formed by mouse hepatocellular carcinoma (HCC) cells and lymphotactin (Lptn) gene modified dendritic cells (DCs). Method: DCs prepared from mouse bone marrow were genetically modified by lymphotactin adenovirus, and fused with H22 cells by polyethylene glycol (PEG). RT-PCR and ELISA were employed to identify lymphotactin expression at mRNA and protein level. Cell phenotypes and fusion efficiency was detected by FACS. The stimulatory effect of DC on T cells was detected by mixed lymphocyte reaction. The cytotoxicity activity against H22 cells was assayed by LDH method. Results: Lymphotactin could be efficiently expressed by DCLptn/H22 hybridoma. DCLptn/H22 cells could induce potent T cell proliferation effect and generate strong cytotoxic T lymphocyte (CTL) reaction against allogenic H22 cells. Conclusion: Lymphotactin genetic modification could enhance the in vitro immune activity of the dendritoma.     

Therapeutic applications of bone marrow-derived stem cells in liver transplantation for end-stage liver diseases

Today, liver transplantation (LT) is the only established treatment for end-stage liver diseases. The de- velopment of LT, including OLT, cadaveric LT, split LT, living donor LT (LDLT), brings hopes to patients with these diseases. However, increasing donor shortage, rejection and life-long immunosuppression with its side effects are the major limitations of this therapy strategy. Bone marrow-derived stem cells (BMDSCs) are capable of differentiating into hepatocyte-like cells and contribute to liver injury repair. The microenvironment of liver injury caused by rejection, ischemia/reperfusion, loss of liver mass, recurrence of HCV and "small-for-size syndrome" after LT can attract a variety of bone marrow-derived stem cell population to the peripheral circulation and then migration to the injury liver to promote the hepatic function restoration. Additionally, BMDSCs can also take part in the functional regeneration of living donor liver after LDLT. This participation in liver regeneration may be associated to the interac- tion between SDF-1and its receptor CXCR4, involving HGF, IL-8, MMP9, and VEGF/VEGFR-2. BMDSC with its bio-characteristics could maintain the allograft tolerance from different angles and in different ways. In conclusion, BMDSCs transplantation, as a new assistant therapeutic method for LT, will ex- pand the space of LT, and provide more survival opportunities for the patients suffering liver diseases in the future.     

Transplanted bone marrow regenerates liver by cell fusion

Results from several experimental systems suggest that cells from one tissue type can form other tissue types after transplantation. This could be due to the presence of multipotential or several types of adult stem cells in donor tissues, or alternatively, to fusion of donor and recipient cells. In a model of tyrosinaemia type I, mice with mutations in the fumarylacetoacetate hydrolase gene (Fah-/-) regain normal liver function after transplantation of Fah+/+ bone marrow cells, and form regenerating liver nodules with normal histology that express Fah. Here we show that these hepatic nodules contain more mutant than wild-type Fah alleles, and that their hepatocytes express both donor and host genes, consistent with polyploid genome formation by fusion of host and donor cells. Using bone marrow cells marked with integrated foamy virus vectors that express green fluorescent protein, we identify common proviral junctions in hepatic nodules and haematopoietic cells. We also show that the haematopoietic donor genome adopts a more hepatocyte-specific expression profile after cell fusion, as the wild-type Fah gene was activated and the pan-haematopoietic CD45 marker was no longer expressed.     

A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease

Transplantation of bone marrow can give rise to graft-versus-host disease when donor T lymphocytes, mismatched with the host for major histocompatability (MHC) antigens, become sensitized and attack host tissues. However, graft-versus-host disease can also arise between donor and host with compatible MHC antigens but mismatched for a minor histocompatability antigen. We report here on the occurrence of severe acute graft-versus-host disease in a male patient with acute myeloid leukaemia who had received bone marrow matched for MHC (HLA) antigens from his sister. Strong cytotoxicity of the posttransplantation (that is, donor) lymphocytes against the patient's pretransplantation lymphocytes was found. Thus, the transplanted lymphocytes differed in a non-HLA antigen from the patient. The possible role of this strong cytotoxic minor histocompatability antigen in the development of graft-versus-host disease in man is being evaluated. Furthermore, with the use of cytotoxic T-cell lines, derived from the patient's 6 day effector cells, we are now able to type for it before grafting.     

慢性粒细胞性白血病骨髓移植后的染色体观察

为了观察慢性白血病骨髓移植术后患者的生存情况，笔者对费城染色体进行了检测，结果表明：患者术后９个月，ＸＸ核型细胞占８７％，ＸＹ核型细胞占１３％，费城染色体阴性；术后１年，ＸＸ核型细胞占６４％，ＸＹ核型细胞占３４％，费城染色体阳性细胞占２％．慢性白血病骨髓移植术后观察费城染色体，能及时反映预后情况     

T-cell specificity for H-2 and Ir gene phenotype correlates with the phenotype of thymic antigen-presenting cells

Experiments with chimaeric animals have demonstrated that the H-2 restriction specificity and immune response (Ir) gene phenotype of the T cell is acquired during development in the thymus. The mechanism by which this process occurs is unclear. One level of obligate expression of H-2 and Ir gene products is on the surface of antigen-presenting cells (APCs) which come from bone marrow precursors. We have now examined the turnover of APCs in the thymuses of F1 leads to parent (P) radiation-induced bone marrow chimaeras and found that APCs of donor phenotype appear at about 2 months after reconstitution. If the peripheral T-cell population is depleted after this time, new T cells emerging from the parental thymus (containing F1 APCs) behaving like F1 T cells, suggesting that cells from the bone marrow can influence thymic-directed T-cell differentiation. The thymic APC is an attractive condidate to play such a part in the development of the T-cell repertoire.     

Cell fusion is the principal source of bone-marrow-derived hepatocytes

Evidence suggests that haematopoietic stem cells might have unexpected developmental plasticity, highlighting therapeutic potential. For example, bone-marrow-derived hepatocytes can repopulate the liver of mice with fumarylacetoacetate hydrolase deficiency and correct their liver disease. To determine the underlying mechanism in this murine model, we performed serial transplantation of bone-marrow-derived hepatocytes. Here we show by Southern blot analysis that the repopulating hepatocytes in the liver were heterozygous for alleles unique to the donor marrow, in contrast to the original homozygous donor cells. Furthermore, cytogenetic analysis of hepatocytes transplanted from female donor mice into male recipients demonstrated 80,XXXY (diploid to diploid fusion) and 120,XXXXYY (diploid to tetraploid fusion) karyotypes, indicative of fusion between donor and host cells. We conclude that hepatocytes derived form bone marrow arise from cell fusion and not by differentiation of haematopoietic stem cells.     

输注体外诱导的同种反应性淋巴细胞诱导大鼠肝脏移植免疫耐受的研究

目的 观察输注体外诱导的同种反应性淋巴细胞,是否可以延长大鼠移植肝脏的存活时间,从而探索一条诱导肝移植免疫耐受的新途径.方法 以供者Lewis大鼠淋巴细胞作为刺激物,体外刺激受者BN大鼠淋巴细胞增殖,应用CFSE（羧基荧光素二醋酸盐琥珀酰亚胺酯）标记法检测增殖情况;将增殖后的BN大鼠淋巴细胞经照射灭活后输注给同品系的BN大鼠,并行Lewis到BN的肝移植,观察肝移植后BN大鼠生存期.结果 同种反应性淋巴细胞体外能够活跃增殖;采用同种反应性淋巴细胞输注可以显著延长肝移植大鼠的存活时间（P＜0.05）.结论 体外诱导的同种反应性淋巴细胞输注,有可能成为诱导抗原特异性免疫耐受的一种新途径.     

Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice

Irradiated MHC-heterozygous mice often reject bone marrow cells transplanted from one of the homozygous parental strains, a phenomenon ('hybrid resistance') that appears to violate the laws of transplantation. Rejection of parental and allogeneic marrow cells also differs from conventional T cell-mediated rejection mechanisms as it is effected by NK1.1+ cells. To account for the unusual specificity of bone marrow rejection, it has been proposed that NK1.1+ cells destroy marrow cells that fail to express the full complement of self MHC class I (MHC-I) molecules. We show here that NK1.1+ cells in normal mice reject haemopoietic transplants from mice that are deficient for normal cell-surface MHC-I expression because of a targeted mutation in the beta 2-microglobulin gene. These findings demonstrate that deficient expression of MHC-I molecules renders marrow cells susceptible to rejection.